Prevention of COVID-19 infection with nasal spray… “The first line of defense like a mask”
(Seoul = Yonhap News) Reporter Kim Jan-di = SK Bioscience[302440]announced on the 13th that it will promote the development of medicines that prevent infections such as the Corona 19 virus by spraying antiviral protein into the nose.
For this project, the Bill & Melinda Gates Foundation supports research and development (R&D) costs, and overseas research institutes such as the International AIDS Vaccine Promotion Center (IAVI) and the University of Washington Antigen Design Institute (IPD) cooperate for development.
If the Gates Foundation supports IAVI for R&D expenses, SK Bioscience will receive regarding $2.2 million (regarding 2.65 billion won) of this in priority from IAVI as an initial development cost.
SK Bioscience will use this amount for initial process research for discovery and production of candidate substances. We plan to cooperate with the IPD on the discovery and development of candidate substances. SK Bioscience has collaborated with IPD to jointly develop the COVID-19 vaccine ‘GBP510’.
Currently, SK Bioscience has begun development and research on the initial process following receiving the IPD’s candidate material technology.
This product is a medicine that prevents infection by forming a protective film inside the nostrils when spraying, preventing the virus from penetrating into our body. It will come in the form of a nasal spray with multiple doses.
An SK Bioscience official explained, “It is sprayed on the nose to form a protective film and acts like a kind of mask that prevents infection.
When this product is commercialized, SK Bioscience expects that it will serve as the first line of defense to preemptively prevent the spread of the virus before vaccines or therapeutics such as masks are developed.
The company also emphasized that nasal spray-type medicines can be stored at room temperature, making manufacturing and distribution easier and one product can be used multiple times.
SK Bioscience plans to build a nasal spray as a platform for pharmaceuticals for the prevention and treatment of respiratory viruses to broadly expand the scope of its application.
Ahn Jae-yong, president of SK Bioscience, said, “If we secure differentiated virus infection prevention and treatment through this research, it will be possible to quickly respond to the continuously evolving respiratory virus.”
(Seoul = Yonhap News) SK Bioscience researchers are conducting research to develop vaccines. 2022.04.13. [SK바이오사이언스 제공. 재판매 및 DB 금지]
Report on Kakao Talk okjebo
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2022/04/13 09:12 Send
